Comparative Pharmacology
Head-to-head clinical analysis: AMEN versus AYGESTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMEN versus AYGESTIN.
AMEN vs AYGESTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progesterone receptor agonist; induces secretory endometrium, inhibits gonadotropin release, and alters cervical mucus.
Progestin that suppresses gonadotropin secretion, inhibits ovulation, and induces endometrial changes by binding to progesterone receptors.
Medroxyprogesterone acetate (AMEN): 5-10 mg orally once daily for 5-10 days, starting on day 16 or 21 of menstrual cycle; also 150 mg IM every 3 months for contraception.
5 mg orally once daily for secondary amenorrhea; 5 mg orally once daily from day 5 to day 25 of menstrual cycle for abnormal uterine bleeding.
None Documented
None Documented
Terminal elimination half-life is approximately 4-6 hours. In severe hepatic impairment, half-life may be prolonged up to 12 hours.
Terminal half-life 5-12 hours; clinical context: requires twice-daily dosing for consistent serum levels.
Primarily hepatic metabolism to inactive metabolites, with <1% excreted unchanged in urine. Fecal elimination of metabolites accounts for ~30%.
Approximately 50-80% renal as metabolites, 10-20% fecal; less than 1% unchanged.
Category C
Category C
Progestin
Progestin